News
NGEN
1.940
-3.96%
-0.080
NervGen Pharma Flags Non-Cash Accounting Errors, Orders Restatement of 2024–2026 Results
TipRanks · 2d ago
NervGen Pharma to restate previously filed financial statements
TipRanks · 2d ago
*NervGen Pharma: Expects to File Restated Audited Financial Statements for Year Ended Dec. 31, 2025, Including Restated 2024 Comparative Figure and Adjustment to Jan. 1, 2024, Opening Balances >NGEN
Dow Jones · 2d ago
NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026
Benzinga · 2d ago
*NervGen Pharma: Restatement Expected to Reduce Previously Reported Accumulated Deficit >NGEN
Dow Jones · 2d ago
*NervGen Pharma: Restatement Expected to Reduce Previously Reported Warrant Liabilities >NGEN
Dow Jones · 2d ago
*NervGen Pharma: Restatement Expected to Reduce Previously Reported Stock-Based Compensation Expense >NGEN
Dow Jones · 2d ago
*NervGen Pharma: Adjustments Have No Effect on Cash and Cash Equivalents, Cash Runway, or Business Operations >NGEN
Dow Jones · 2d ago
*NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
Dow Jones · 2d ago
Nervgen’s RESTORE Trial Moves Toward Launch: What NVG-291 Could Mean for NGEN Investors
TipRanks · 2d ago
NervGen Pharma Appoints KPMG US as New Auditor After Canadian Resignation
TipRanks · 3d ago
Weekly Report: what happened at NGEN last week (0914-0918)?
Weekly Report · 09/21 09:05
Weekly Report: what happened at NGEN last week (0907-0911)?
Weekly Report · 09/14 09:05
Weekly Report: what happened at NGEN last week (0831-0904)?
Weekly Report · 09/07 09:05
Weekly Report: what happened at NGEN last week (0824-0828)?
Weekly Report · 08/31 09:05
Weekly Report: what happened at NGEN last week (0817-0821)?
Weekly Report · 08/24 09:05
Analysts Are Bullish on Top Healthcare Stocks: Auxly Cannabis Group (CBWTD), Genelux Corp. (GNLX)
TipRanks · 08/17 10:30
Weekly Report: what happened at NGEN last week (0810-0814)?
Weekly Report · 08/17 09:05
NervGen Pharma reports Q2 EPS (C$0.37) vs. (C$0.13) last year
TipRanks · 08/17 07:59
NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position
TipRanks · 08/13 12:01
More
Webull provides a variety of real-time NGEN stock news. You can receive the latest news about Nervgen Pharma Corp through multiple platforms. This information may help you make smarter investment decisions.
About NGEN
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.